GPNMB and neoplasm: An exploratory biomarker analysis from EMERGE also suggested that patients with advanced TNBC overexpressing gpNMB (i.e., ≥25% tumor epithelial cells staining positive by immunohistochemistry (IHC)) were most likely to derive greater benefit from GV, compared with standard chemotherapies.